File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0301-472X(01)00654-3
- Scopus: eid_2-s2.0-0034955676
- PMID: 11438214
- WOS: WOS:000170057400013
- Find via
Supplementary
- Citations:
- Appears in Collections:
Conference Paper: Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations
Title | Human CD34<sup>+</sup> cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34<sup>-</sup> cell preparations |
---|---|
Authors | |
Issue Date | 2001 |
Citation | Experimental Hematology, 2001, v. 29, n. 7, p. 910-921 How to Cite? |
Abstract | Objective. The CD34 cell surface marker is used widely for stem/progenitor cell isolation. Since several recent studies reported that CD34- cells also have in vivo engrafting capacity, we quantitatively compared the engraftment potential of CD34+ vs CD34- cell preparations from normal human placental/umbilical cord blood (CB), bone marrow (BM), and mobilized peripheral blood (PBSC) specimens, using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model. Methods. CD34+ and CD34- cell preparations were purified by four different approaches in 14 individual experiments involving 293 transplanted NOD/SCID mice. In most experiments, CD34+ cells were depleted twice (CD34=) in order to obtain efficient depletion of CD34+ cells from the CD34- cell preparations. Results. Dose-dependent levels of human hematopoietic cells were observed after transplantation of CD34+ cell preparations. To rigorously assess the complementary CD34- cell preparations, cell doses 10- to 1000-fold higher than the minimum dose of the CD34+ cell preparations necessary for engraftment were transplanted. Nevertheless, of 125 NOD/SCID mice transplanted with CD34- cell preparations purified from the same starting cells, only six mice had detectable human hematopoiesis, by flow cytometric or PCR assay. Conclusions. CD34- cells provide only a minor contribution to hematopoietic engraftment in this in vivo model system, as compared to CD34+ cells from the same samples of noncultured human cells. Hematopoiesis derived from actual CD34- cells is difficult to distinguish from that due to CD34+ cells potentially contaminating the preparations. Copyright © 2001 International Society for Experimental Hematology. |
Persistent Identifier | http://hdl.handle.net/10722/294486 |
ISSN | 2023 Impact Factor: 2.5 2023 SCImago Journal Rankings: 1.157 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gao, Zhigang | - |
dc.contributor.author | Fackler, Mary Jo | - |
dc.contributor.author | Leung, Wing | - |
dc.contributor.author | Lumkul, Rachata | - |
dc.contributor.author | Ramirez, Manuel | - |
dc.contributor.author | Theobald, Narda | - |
dc.contributor.author | Malech, Harry L. | - |
dc.contributor.author | Civin, Curt I. | - |
dc.date.accessioned | 2020-12-03T08:22:51Z | - |
dc.date.available | 2020-12-03T08:22:51Z | - |
dc.date.issued | 2001 | - |
dc.identifier.citation | Experimental Hematology, 2001, v. 29, n. 7, p. 910-921 | - |
dc.identifier.issn | 0301-472X | - |
dc.identifier.uri | http://hdl.handle.net/10722/294486 | - |
dc.description.abstract | Objective. The CD34 cell surface marker is used widely for stem/progenitor cell isolation. Since several recent studies reported that CD34- cells also have in vivo engrafting capacity, we quantitatively compared the engraftment potential of CD34+ vs CD34- cell preparations from normal human placental/umbilical cord blood (CB), bone marrow (BM), and mobilized peripheral blood (PBSC) specimens, using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model. Methods. CD34+ and CD34- cell preparations were purified by four different approaches in 14 individual experiments involving 293 transplanted NOD/SCID mice. In most experiments, CD34+ cells were depleted twice (CD34=) in order to obtain efficient depletion of CD34+ cells from the CD34- cell preparations. Results. Dose-dependent levels of human hematopoietic cells were observed after transplantation of CD34+ cell preparations. To rigorously assess the complementary CD34- cell preparations, cell doses 10- to 1000-fold higher than the minimum dose of the CD34+ cell preparations necessary for engraftment were transplanted. Nevertheless, of 125 NOD/SCID mice transplanted with CD34- cell preparations purified from the same starting cells, only six mice had detectable human hematopoiesis, by flow cytometric or PCR assay. Conclusions. CD34- cells provide only a minor contribution to hematopoietic engraftment in this in vivo model system, as compared to CD34+ cells from the same samples of noncultured human cells. Hematopoiesis derived from actual CD34- cells is difficult to distinguish from that due to CD34+ cells potentially contaminating the preparations. Copyright © 2001 International Society for Experimental Hematology. | - |
dc.language | eng | - |
dc.relation.ispartof | Experimental Hematology | - |
dc.title | Human CD34<sup>+</sup> cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34<sup>-</sup> cell preparations | - |
dc.type | Conference_Paper | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/S0301-472X(01)00654-3 | - |
dc.identifier.pmid | 11438214 | - |
dc.identifier.scopus | eid_2-s2.0-0034955676 | - |
dc.identifier.volume | 29 | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | 910 | - |
dc.identifier.epage | 921 | - |
dc.identifier.isi | WOS:000170057400013 | - |
dc.identifier.issnl | 0301-472X | - |